median of one vessel treated per patient and a mean preoperative pedal runoff score of 12 that improved to a mean of 6 after intervention (<7 is considered good pedal runoff); 34% of interventions were a direct revascularization of the intended angiosome. Overall major adverse cardiovascular event rate was <1% at 90 days after the procedure. The majority of patients underwent some form of planned forefoot amputations (single digit, multiple digits, ray amputation, or transmetatarsal amputation). Wound healing at 3 months was 76%. Those who failed to heal underwent below-knee amputations. The clinical efficacy was 25% 6 7% (mean 6 standard error of the mean) at 5 years. The 5-year amputation-free survival rate was 33% 6 8%, and the 5-year major adverse limb event rate was 27% 6 9%. On Cox proportional multivariate analysis, predictors for amputation-free survival were absence of significant coronary disease, a pedal runoff <7, WIfI stage 3 disease, and absence of end-stage renal disease. Predictors for wound healing were improved pedal runoff score (<7), absence of infection, direct angiosome revascularization, and absence of end-stage renal disease.
VESS04.
Objective: Early outcomes and late mortality after open extent I to III thoracoabdominal aneurysm (TAAA) repair are well described; however, late graft and aortic events are poorly understood. This study investigated long-term aortic and graft outcomes as these data are increasingly important as endovascular repair matures.
Methods: During 28 years, 516 patients underwent repair (type I, n ¼ 177 [34%]; type II, n ¼ 100 [20%]; type III, n ¼ 239 [46%]). Patients were monitored for late events. Late aortic events were defined as native aortic disease leading to death or further intervention. Planned secondary procedures were excluded. Graft complications included anastomotic aneurysm, graft infection, and branch occlusion. Variables were assessed for association with end points using log-rank methods and Cox proportional hazards regression. Time-to-event analysis was performed using Kaplan-Meier methods.
Results: In-hospital mortality occurred in 40 patients (8%), leaving 476 for surveillance. Age was 69.8 6 10.5 years. Mean follow-up was 4.9 6 4.6 years. [n ¼ 12] ; renovisceral occlusion/repair [n ¼ 9 (1.9%); side arm graft, n ¼ 8; native, n ¼ 1]; anastomotic stricture, n ¼ 1]) occurring at 4.7 6 4.5 years. Variables predictive of graft-related complication were type II extent (HR, 3.4; P ¼ .002) and distal aortic perfusion/motor evoked potential monitoring (HR, 3.6; P ¼ .02). Freedom from aortic or graft-related event was 80% at 5 years. Freedom from any aortic or graft reintervention was 84% at 5 years. Aorta-related mortality in follow-up was 2.7% and estimated to be 3.1% at 5 years. Overall survival was 67% and 44% at 5 and 10 years, respectively.
Conclusions: After type I to type III TAAA repair, late aortic and graftrelated events are infrequent. Native aortic disease sequelae are more common than graft complication. Aortic events are predicted by complex operation and degree of remaining aorta. Extensive reconstruction drives graft-related events. Ultimately, need for reintervention is rare, and aorta-related mortality is low. These findings verify durability of extensive TAAA repair and serve as benchmarks for endovascular repair.
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VESS05.
In Objective: Transcarotid artery revascularization (TCAR) offers a less invasive option to carotid endarterectomy (CEA) in high-risk patients and has the lowest reported overall stroke rate for any prospective trial of carotid artery stenting. This study compares initial in-hospital outcomes of CEA and TCAR using the Society for Vascular Surgery (SVS) Vascular Quality Initiative TCAR Surveillance Project done in collaboration with the Centers for Medicare and Medicaid Services to create more information for future coverage decisions.
Methods: The SVS TCAR Surveillance Project is designed to evaluate the safety and efficacy of TCAR in real-world practice, using a contemporary comparison to CEA. Patients enrolled in this project were compared with those undergoing CEA during the same period (2016) (2017) . The primary outcome was a composite of in-hospital stroke and death. Average treatment effects were estimated by augmented inverse-probability weighting. Additional analysis was performed using multivariable logistic regression as well as various matching techniques, such as propensity score matching and coarsened exact matching. Adjusted analysis accounted for age, sex, race, insurance status, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, symptomatic status, restenosis, prior vascular procedures, degree of ipsilateral stenosis, and preoperative medication use.
Results: A total of 637 patients underwent TCAR compared with 12,049 patients who underwent CEA. Patients undergoing TCAR were older, more likely to be symptomatic, and had more medical comorbidities, such as coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and prior vascular procedures, compared with CEA patients (Table) . The majority of TCAR procedures were done under local/regional anesthesia (95.3% vs 9.7% in CEA; P < .001). On average, TCAR was 36.7 minutes shorter than CEA (78.0 6 33.9 vs 114.7 6 42.5 minutes; P < .001). On univariate analysis, there were no differences in the rates of in-hospital stroke/death (1.3% vs 1.7%; P ¼ .42), overall neurologic events (2.0% vs 1.9%; P ¼ .83), in-hospital myocardial infarction (0.7% vs 1.1%; P ¼ .31), and 30-day mortality (0.5% vs 0.9%; P ¼ .08) between CEA and TCAR, respectively. Patients undergoing CEA had higher rates of cranial nerve injury (2.8% vs 0.8%; P < .01) and postoperative hypertension (18.3% vs 11.6%; P < .001) compared with TCAR patients. On multivariable analysis and using different matching methods, there were no differences in overall stroke, stroke/death, or overall neurologic events (Fig) . The absolute difference in adjusted stroke/death rates between the two groups was 0.3% (95% confidence interval, À1.7% to 1.0%; P ¼ .64).
Conclusions: Despite a substantially higher medical risk in patients undergoing TCAR, analysis of the preliminary results from the SVS Vascular Quality Initiative TCAR Surveillance Project showed similar in-hospital stroke/death rates between TCAR and CEA after multivariable adjustment and rigorous matching. Further studies with larger sample sizes and longer follow-up will be needed to establish the equivalence of TCAR compared with CEA. Objective: Intravascular ultrasound (IVUS) has become an important adjuvant diagnostic tool in the treatment of deep venous disease. This study sought to create an IVUS-based scoring system that may predict stent failure in the treatment May-Thurner syndrome.
Methods: There were 118 consecutive patients with May-Thurner syndrome who underwent IVUS-guided stent placement from April 2009 to May 2015 (73 months) at two collaborating institutions. Patients included 86 (73%) women and 32 (27%) men with a mean age of 46 years (range, 17-83 years); 45 (38%), 30 (27%), 25 (21%), and 18 (15%) patients had Clinical, Etiology, Anatomy, and Pathophysiology class 3, 4, 5, and 6 disease, respectively. An IVUS-driven scoring system was derived to assess type of May-Thurner syndrome (nonocclusive or occlusive), disease chronicity (nonthrombotic, acute, or chronic), venous disease length (<180 mm or >181 mm), venous inflow compliance (presence or absence of respiratory variation), iliocaval confluence disease involvement (present or absent), iliocaval confluence stenting obligation (stented or spared), and presence of perivenous collaterals before and after stenting (none or resolved). Six categories were scored with 0 or 1 and one category was scored with 0, 1, or 2. Scores were tabulated for each patient at the time of initial intervention. Patients who developed moderate (>50%) in-stent stenosis, required thrombolysis, or underwent additional stenting procedures during a 2-year period were identified and considered treatment failures.
Results: There were 118 (100%) patients who received anticoagulation and 78 (66%) who were taking an antiplatelet agent. Of the 118 patients, 38 (32%) developed moderate (>50%) in-stent stenosis, required thrombolysis, or underwent additional stenting procedures and were considered treatment failures during the observed period; 80 (68%) required no additional intervention and were considered treatment successes. Overall, mean IVUS score for the entire population was 5.22 (6 1.40). The mean IVUS score in the treatment failure cohort was 5.64 (6 1.20) compared with a score of 4.67 (6 1.47) in the treatment success group (P ¼ .0081). Patients with a score above 4 on this 7-point scale had an increased relative risk to stent failure at 2 years (relative risk, 1.6).
Conclusions: An IVUS-driven scoring system score of 4 or greater during initial intervention for May-Thurner syndrome predicts failure at 2 years. Additional treatment modalities should be considered at implantation to prevent failure. 
